285 related articles for article (PubMed ID: 25166308)
1. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization.
Navis M; Tran K; Bale S; Phad GE; Guenaga J; Wilson R; Soldemo M; McKee K; Sundling C; Mascola J; Li Y; Wyatt RT; Karlsson Hedestam GB
PLoS Pathog; 2014 Aug; 10(8):e1004337. PubMed ID: 25166308
[TBL] [Abstract][Full Text] [Related]
2. Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.
Spencer DA; Malherbe DC; Vázquez Bernat N; Ádori M; Goldberg B; Dambrauskas N; Henderson H; Pandey S; Cheever T; Barnette P; Sutton WF; Ackerman ME; Kobie JJ; Sather DN; Karlsson Hedestam GB; Haigwood NL; Hessell AJ
J Immunol; 2021 Mar; 206(5):999-1012. PubMed ID: 33472907
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
4. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
[TBL] [Abstract][Full Text] [Related]
5. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
Yuan T; Li J; Zhang MY
MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
[TBL] [Abstract][Full Text] [Related]
6. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
[TBL] [Abstract][Full Text] [Related]
7. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.
Duan H; Chen X; Boyington JC; Cheng C; Zhang Y; Jafari AJ; Stephens T; Tsybovsky Y; Kalyuzhniy O; Zhao P; Menis S; Nason MC; Normandin E; Mukhamedova M; DeKosky BJ; Wells L; Schief WR; Tian M; Alt FW; Kwong PD; Mascola JR
Immunity; 2018 Aug; 49(2):301-311.e5. PubMed ID: 30076101
[TBL] [Abstract][Full Text] [Related]
8. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
9. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.
Hicar MD; Chen X; Kalams SA; Sojar H; Landucci G; Forthal DN; Spearman P; Crowe JE
Mol Immunol; 2016 Feb; 70():94-103. PubMed ID: 26748387
[TBL] [Abstract][Full Text] [Related]
10. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
11. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
Front Immunol; 2018; 9():3163. PubMed ID: 30697215
[TBL] [Abstract][Full Text] [Related]
12. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
13. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
14. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.
Tran K; Poulsen C; Guenaga J; de Val N; Wilson R; Sundling C; Li Y; Stanfield RL; Wilson IA; Ward AB; Karlsson Hedestam GB; Wyatt RT
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):E738-47. PubMed ID: 24550318
[TBL] [Abstract][Full Text] [Related]
16. Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.
Dubrovskaya V; Guenaga J; de Val N; Wilson R; Feng Y; Movsesyan A; Karlsson Hedestam GB; Ward AB; Wyatt RT
PLoS Pathog; 2017 Sep; 13(9):e1006614. PubMed ID: 28902916
[TBL] [Abstract][Full Text] [Related]
17. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.
Parks KR; MacCamy AJ; Trichka J; Gray M; Weidle C; Borst AJ; Khechaduri A; Takushi B; Agrawal P; Guenaga J; Wyatt RT; Coler R; Seaman M; LaBranche C; Montefiori DC; Veesler D; Pancera M; McGuire A; Stamatatos L
Cell Rep; 2019 Dec; 29(10):3060-3072.e7. PubMed ID: 31801073
[TBL] [Abstract][Full Text] [Related]
19. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
[TBL] [Abstract][Full Text] [Related]
20. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
